Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Inclusion Criteria:

Women >= 18 years of age
Established diagnosis of breast cancer stages I-IV
On endocrine therapy including tamoxifen or aromatase inhibitors with or without concurrent use of ovarian function suppression
Self-reporting hair loss since starting endocrine therapy

Exclusion Criteria:

Pregnant or nursing women
Current chemotherapy use or prior chemotherapy use within the last 2 years
History of scarring/cicatricial alopecia or alopecia areata
Prior use of oral or topical minoxidil
Prior or ongoing use of spironolactone
Known sensitivity to minoxidil
Untreated hypothyroidism or iron deficiency as determined by thyroid stimulating hormone (TSH) with reflex free T4 and ferritin level > 40 to be checked at the time of enrolling if not completed in the 12 months prior